Screener
Ligand Pharmaceuticals LGND Financial Royalty Assets, Allowance
Financial Royalty Assets, Allowance at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
| Others | 5,729 | (212) | 5,517 | 5,769 | (214) | 5,555 |
| Total financial royalty assets, net | $209,699 | $(2,489) | $207,210 | $222,375 | $(2,706) | $219,669 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's financial royalty assets, allowance?
- Ligand Pharmaceuticals (LGND) reported financial royalty assets, allowance of $2.49M in Q2 2026.
- How has Ligand Pharmaceuticals's financial royalty assets, allowance changed year-over-year?
- Ligand Pharmaceuticals's financial royalty assets, allowance decreased by 10.7% year-over-year, from $2.79M to $2.49M.
- What is the long-term trend for Ligand Pharmaceuticals's financial royalty assets, allowance?
- Over 2 years (2023 to 2025), Ligand Pharmaceuticals's financial royalty assets, allowance has grown at a -42.1% compound annual growth rate (CAGR), from $8.07M to $2.71M.
- What does financial royalty assets, allowance mean?
- Financial Royalty Assets, Allowance as reported by Ligand Pharmaceuticals Inc..
Ask your AI about Ligand Pharmaceuticals's financial royalty assets, allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude